All posts by: Michael Zand

About Michael Zand

Gene Therapy in Muscular Dystrophy – Muscular Dystrophy News

Continue reading

2018-02-11 NEWS

Gene Therapy in Muscular Dystrophy
Muscular Dystrophy News
Dystrophin is part of a protein complex that strengthens and protects muscle fibers. When the cells don’t have functional dystrophin due to the gene mutation, muscles progressively weaken. Scientists think that supplying a gene that codes for a

Continue reading

2018-02-11 NEWS

BMS Immunotherapy Combo Study Backs FoundationOne CDx Tumor Mutational Burden Indication
360Dx
NEW YORK (GenomeWeb) – A study evaluating the combination of Bristol-Myers Squibb’s immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) may support regulatory approval for the regimen as an option for lung cancer patients with a large number of

Continue reading

2018-02-11 NEWS

BMS Immunotherapy Combo Study Backs FoundationOne CDx Tumor Mutational Burden Indication
360Dx
NEW YORK (GenomeWeb) – A study evaluating the combination of Bristol-Myers Squibb’s immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) may support regulatory approval for the regimen as an option for lung cancer patients with a large number of

Continue reading

2018-02-11 NEWS

Medical Xpress

New immunotherapy combination tolerable, effective in patients with advanced kidney cancer
Medical Xpress
The immunotherapy agent, pembrolizumab, is an immune checkpoint inhibitor that blocks a self-defense mechanism used by cancer cells to evade attack and destruction by the body’s immune cells. It is FDA-approved for the treatment of patients with
New combo therapy found effective in kidney cancer patientsDaijiworld.com

all 2 news articles »